{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:22:02Z","timestamp":1792174922678,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DP2DA053720"],"award-info":[{"award-number":["DP2DA053720"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA058352"],"award-info":[{"award-number":["R01DA058352"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P30MH116867"],"award-info":[{"award-number":["P30MH116867"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P30MH133399"],"award-info":[{"award-number":["P30MH133399"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Although people who inject drugs (PWID) are at high risk of acquiring HIV, knowledge and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among this population remain low due to numerous psychosocial and structural barriers. Multiple implementation strategies have been proposed to address this gap, notably providing long-acting injectable (LAI) formulations of PrEP and offering PrEP at syringe services programs (SSPs). This qualitative study explores the acceptability and feasibility of offering LAI-PrEP for PWID at risk for HIV at Florida\u2019s first legal SSP. In-depth semi-structured interviews were conducted with PWID (<jats:italic>n<\/jats:italic>\u2009=\u200925) and healthcare providers (<jats:italic>n<\/jats:italic>\u2009=\u20095), and transcripts were analyzed using iterative thematic analysis. The provision of LAI-PrEP at the SSP was overwhelmingly acceptable to both PWID and providers, and specific advantages and disadvantages of LAI-PrEP compared to oral PrEP among this population were elucidated. Likewise, PWID and providers identified facilitators and barriers to offering LAI-PrEP at the SSP and proposed recommendations for implementation. Overall, this study adds to the growing evidence that provision of LAI-PrEP at SSPs is acceptable and feasible and holds promise in expanding access to and uptake of HIV prevention services among PWID.<\/jats:p>","DOI":"10.1007\/s10461-024-04598-3","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:47:21Z","timestamp":1736383641000},"page":"1235-1246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-Acting Injectable Prep for People Who Inject Drugs at a Syringe Services Program: A Qualitative Acceptability and Feasibility Study"],"prefix":"10.1007","volume":"29","author":[{"suffix":"Jr.","given":"Edward","family":"Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel E.","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Plesons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Serota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"St. George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-0812","authenticated-orcid":false,"given":"Tyler S.","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"1","key":"4598_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2105\/AJPH.2019.305380","volume":"110","author":"BP Giroir","year":"2020","unstructured":"Giroir BP. The time is now to end the HIV Epidemic. Am J Public Health. 2020;110(1):22\u20134.","journal-title":"Am J Public Health"},{"key":"4598_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijid.2020.09.011","volume":"100","author":"Y Assefa","year":"2020","unstructured":"Assefa Y, Gilks CF. Ending the epidemic of HIV\/AIDS by 2030: will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries? Int J Infect Dis. 2020;100:273\u20137.","journal-title":"Int J Infect Dis"},{"key":"4598_CR3","doi-asserted-by":"crossref","unstructured":"Karch DL et al. HIV Infection Care and Viral Suppression Among People Who Inject Drugs, 28 U.S. Jurisdictions, 2012\u20132013. Open AIDS J. 2016; 10:127\u2013135., 2016. 10.","DOI":"10.2174\/1874613601610010127"},{"issue":"6","key":"4598_CR4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s10461-018-2284-1","volume":"23","author":"N Kim","year":"2019","unstructured":"Kim N, et al. Undiagnosed and untreated HIV infection among persons who inject drugs: results of three National HIV behavioral surveillance surveys, San Francisco, 2009\u20132015. AIDS Behav. 2019;23(6):1586\u20139.","journal-title":"AIDS Behav"},{"issue":"1","key":"4598_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2105\/AJPH.2019.305366","volume":"110","author":"C Alpren","year":"2020","unstructured":"Alpren C, et al. Opioid use fueling HIV Transmission in an urban setting: an outbreak of HIV infection among people who inject Drugs-Massachusetts, 2015\u20132018. Am J Public Health. 2020;110(1):37\u201344.","journal-title":"Am J Public Health"},{"issue":"1","key":"4598_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","volume":"14","author":"J Carter","year":"2019","unstructured":"Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019;14(1):20.","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"4598_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/apc.2022.0068","volume":"36","author":"AR Bazzi","year":"2022","unstructured":"Bazzi AR, et al. Long-acting Injectable Human Immunodeficiency Virus Pre-exposure Prophylaxis Preferred Over other modalities among people who inject drugs: findings from a qualitative study in California. AIDS Patient Care STDS. 2022;36(7):254\u201362.","journal-title":"AIDS Patient Care STDS"},{"issue":"10","key":"4598_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/09540121.2019.1587356","volume":"31","author":"KB Biello","year":"2019","unstructured":"Biello KB, et al. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs. AIDS Care. 2019;31(10):1214\u201320.","journal-title":"AIDS Care"},{"issue":"1","key":"4598_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12879-022-07572-3","volume":"22","author":"AR King","year":"2022","unstructured":"King AR, et al. Acceptability of injectable pre-exposure prophylaxis among people who inject drugs in three urban U.S. settings. BMC Infect Dis. 2022;22(1):737.","journal-title":"BMC Infect Dis"},{"key":"4598_CR10","doi-asserted-by":"publisher","first-page":"108058","DOI":"10.1016\/j.jsat.2020.108058","volume":"117","author":"R Shrestha","year":"2020","unstructured":"Shrestha R, et al. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. J Subst Abuse Treat. 2020;117:108058.","journal-title":"J Subst Abuse Treat"},{"key":"4598_CR11","doi-asserted-by":"crossref","unstructured":"Walters SM et al. PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure. AIDS Behav, 2021: pp. 1\u201313.","DOI":"10.1007\/s10461-021-03488-2"},{"issue":"1","key":"4598_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s12889-023-15429-w","volume":"23","author":"AR Bazzi","year":"2023","unstructured":"Bazzi AR, et al. Study protocol for an efficacy trial of the PrEP for Health intervention to increase HIV PrEP use among people who inject drugs. BMC Public Health. 2023;23(1):513.","journal-title":"BMC Public Health"},{"issue":"4","key":"4598_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11606-022-07672-5","volume":"38","author":"AR Bazzi","year":"2023","unstructured":"Bazzi AR, et al. Patient and provider perspectives on a Novel, low-threshold HIV PrEP Program for people who inject drugs experiencing homelessness. J Gen Intern Med. 2023;38(4):913\u201321.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"4598_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12954-022-00718-1","volume":"19","author":"A Corneli","year":"2022","unstructured":"Corneli A, et al. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine\/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation. Harm Reduct J. 2022;19(1):132.","journal-title":"Harm Reduct J"},{"issue":"4","key":"4598_CR15","doi-asserted-by":"publisher","first-page":"e0231424","DOI":"10.1371\/journal.pone.0231424","volume":"15","author":"Y Jo","year":"2020","unstructured":"Jo Y, et al. Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. PLoS ONE. 2020;15(4):e0231424.","journal-title":"PLoS ONE"},{"key":"4598_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drugalcdep.2018.08.014","volume":"195","author":"SG Sherman","year":"2019","unstructured":"Sherman SG, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148\u201355.","journal-title":"Drug Alcohol Depend"},{"key":"4598_CR17","doi-asserted-by":"publisher","first-page":"109124","DOI":"10.1016\/j.drugalcdep.2021.109124","volume":"229","author":"HE Tookes","year":"2021","unstructured":"Tookes HE, et al. Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs. Drug Alcohol Depend. 2021;229:109124.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"4598_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12954-022-00721-6","volume":"19","author":"TS Bartholomew","year":"2022","unstructured":"Bartholomew TS, et al. We want everything in a one-stop shop: acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for black people who inject drugs. Harm Reduct J. 2022;19(1):133.","journal-title":"Harm Reduct J"},{"issue":"1","key":"4598_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/07853890.2023.2182908","volume":"55","author":"E Suarez","year":"2023","unstructured":"Suarez E, et al. Adaptation of the Tele-Harm reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study. Ann Med. 2023;55(1):733\u201343.","journal-title":"Ann Med"},{"issue":"7","key":"4598_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, et al. Cabotegravir for HIV Prevention in Cisgender men and Transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"5","key":"4598_CR21","doi-asserted-by":"publisher","first-page":"e048478","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"EO Murchu","year":"2022","unstructured":"Murchu EO, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5):e048478.","journal-title":"BMJ Open"},{"key":"4598_CR22","doi-asserted-by":"crossref","unstructured":"Philbin MM, et al. Long-acting Injectable ART and PrEP among women in six cities across the United States: a qualitative analysis of who would benefit the most. AIDS Behav; 2021.","DOI":"10.1007\/s10461-021-03483-7"},{"issue":"7","key":"4598_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/apc.2022.0068","volume":"36","author":"Bazzi","year":"2022","unstructured":"Bazzi, et al. Long-acting Injectable Human Immunodeficiency Virus Pre-exposure Prophylaxis Preferred Over other modalities among people who inject drugs: findings from a qualitative study in California. AIDS Patient Care STDS. 2022;36(7):254\u201362.","journal-title":"AIDS Patient Care STDS"},{"key":"4598_CR24","doi-asserted-by":"crossref","unstructured":"Eger WH, et al. Long-acting Injectable PrEP interest and general PrEP awareness among people who inject drugs in the San Diego-Tijuana Border Metroplex. AIDS Behav; 2024.","DOI":"10.1007\/s10461-024-04285-3"},{"issue":"6","key":"4598_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"1","key":"4598_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12889-018-6314-8","volume":"19","author":"AR Bazzi","year":"2019","unstructured":"Bazzi AR, et al. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions. BMC Public Health. 2019;19(1):31\u201331.","journal-title":"BMC Public Health"},{"key":"4598_CR27","unstructured":"CDC. Pre-exposure prophylaxis for the prevention of HIV infection in the United States\u2013\u20092021 update: A clinical practice guideline. 2021."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-024-04598-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T21:02:47Z","timestamp":1744318967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-024-04598-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4598"],"URL":"https:\/\/doi.org\/10.1007\/s10461-024-04598-3","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Miami Institutional Review Board in March of 2022 (IRB# 20220127). Informed consent was obtained from all participants included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: TSB and HET receive research funding from Gilead Sciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}